Shanghai Allist Pharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of tumor-targeted drugs in China in internationally...
Transthera wins China NMPA clearance for Phase II TT-00973 combo trial in EGFR-mutant NSCLC
Allist released its performance for the first three quarters, with a net profit attributable to the parent company of 1.616 billion yuan, a year-on-year increase of 52.01%
Allist: The net profit for the third quarter was 565 million yuan, a year-on-year increase of 38.77%
Allist conducted a block trade today at a discount, with 488,700 shares traded and a transaction amount of 51.1327 million yuan
Allist today conducted a block trade of 520,000 shares at a discount, with a transaction amount of 54.5532 million yuan
Today, a total of 99 stocks had block trades, with a total transaction amount of 2.8 billion yuan